Norfloxacin Therapy for Patients With Cirrhosis and Severe Liver Failure
Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Patients with advanced cirrhosis have abnormal translocation of Gram-negative bacteria across
the intestinal barrier and subsequent systemic inflammatory response. We hypothesized that
this translocation may worsen the underlying liver disease. Thus, the aim of this trial was
to assess the effects of the oral administration of norfloxacin (an antibiotic that
suppresses intestinal Gram-negative bacteria) on the development of complications of
cirrhosis.